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Jernej Štukelj,*,†,‡ Sami Svanbac̈k,‡,† Julijana Kristl,§ Clare J. Strachan,† and Jouko Yliruusi†
†Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
‡The Solubility Company, Viikinkaari 6, 00790 Helsinki, Finland
§University of Ljubljana, Faculty of Pharmacy, Asǩercěva 7, 1000 Ljubljana, Slovenia
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ABSTRACT: Solubility is a physicochemical property highly
dependent on the solid-state form of a compound. Thus,
alteration of a compound’s solid-state form can be undertaken
to enhance the solubility of poorly soluble drug compounds.
In the Biopharmaceutics Classification System (BCS), drugs
are classified on the basis of their aqueous solubility and
permeability. However, aqueous solubility does not always
correlate best with in vivo solubility and consequently
bioavailability. Therefore, the use of biorelevant media is a
more suitable approach for mimicking in vivo conditions.
Here, assessed with a novel image-based single-particle-
analysis (SPA) method, we report a constant ratio of
solubility increase of 3.3 ± 0.5 between the α and γ solid-
state forms of indomethacin in biorelevant media. The ratio was independent of pH, ionic strength, and surfactant
concentration, which all change as the drug passes through the gastrointestinal tract. On the basis of the solubility ratio, a free-
energy difference between the two polymorphic forms of 2.9 kJ/mol was estimated. Lastly, the use of the SPA approach to
assess solubility has proven to be simple, fast, and both solvent- and sample-sparing, making it an attractive tool for drug
development.
The effect of a drug in the body is a consequence of anintriguing interplay on the molecular level, with potency
and selectivity being two values we use to characterize it. These
two parameters, as crucial as they might seem, are not vital in
determining the developability of a drug: stability and
solubility are.1−3 Furthermore, solubility is not only a
molecular property; it is also highly governed by a compound’s
solid-state form.2,4
The rise of a new solid-state form in drug development can
cause serious complications. Norvir is an illustrative example;
two years after the product was launched, ritonavir, the active
ingredient, transformed from Form I into a more thermody-
namically stable Form II.5 The new polymorph exhibited
significantly reduced solubility resulting in lower bioavail-
ability. Therefore, for a compound entering the development
stage, it is wise to have a well-established polymorphic map
with the corresponding thermodynamic relationships. Ther-
modynamic relationships are usually approached through the
means of thermal analysis but can also be estimated from
solubility data.6,7 The obtained knowledge may thereafter be
used for the deliberate alteration of a compound’s solid-state
form as an option to enhance its druglike properties (i.e.,
solubility).8,9 This is especially true in these times of high-
throughput screening (HTS) and combinatorial chemistry,
when poor aqueous solubility is becoming a major issue in the
drug-development process.3,4
In its most basic definition, thermodynamic-equilibrium
solubility refers to the maximum amount of the most stable
crystalline form of the compound that can remain dissolved in
a given volume of the solvent at a given temperature and
pressure.8,10,11 The solubility of higher-energy solid-state forms
(i.e., amorphous and metastable polymorphic forms) is
referred to as “apparent solubility”.9,12 Therefore, starting the
solubility measurement with a higher-energy solid-state form
will initially produce the apparent solubility, but given enough
time, the thermodynamic-equilibrium solubility of the most
stable form will eventually dominate.
On the basis of aqueous solubility and permeability over a
pH range of 1−7.5, drugs are categorized using the
Biopharmaceutics Classification System (BCS).13 Over the
time the BCS has been in use, it has become apparent that
further refinements are required, especially with regard to the
in vivo correlation between dissolution and solubility.14
Bergström et al. showed that the apparent BCS classification
Received: November 15, 2018
Accepted: February 20, 2019
Published: February 20, 2019
Article
pubs.acs.org/acCite This: Anal. Chem. 2019, 91, 3997−4003
© 2019 American Chemical Society 3997 DOI: 10.1021/acs.analchem.8b05290
Anal. Chem. 2019, 91, 3997−4003
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
D
ow
nl
oa
de
d 
vi
a 
U
N
IV
 O
F 
H
EL
SI
N
K
I o
n 
A
pr
il 
24
, 2
01
9 
at
 0
7:
46
:5
2 
(U
TC
). 
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
. 
of some compounds could shift when dissolved in biorelevant
media.15
Biorelevant media simulate gastric or intestinal fluid in a fed
or fasted state by containing various additives.16,17 The most
important with respect to drug dissolution are the surfactants
(i.e., lecithin and sodium taurocholate). These amphiphilic
molecules arrange themselves onto the solid−liquid interface
and modify the wetting behavior by reduction of the contact
angle between the drug and the liquid. Moreover, if the critical
micellar concentration is exceeded, the drug molecules can
become incorporated inside the self-assembled surfactant
structures (micelles).18 Finally, in addition to the solubility,
surfactants can also affect the polymorphic changes of a
dissolving compound, as shown by Lehto and co-workers.19
The aim of the present study was to investigate the solubility
of polymorphs of indomethacin, a BCS class II drug, in
biorelevant media. Solubility measurements were conducted
utilizing the newly developed image-based single-particle-
analysis (SPA) method.20 The method combines optics with
fluidics and enables measurement of solubility with less than
0.1 mg of a compound on the basis of the dissolution rate.
With the SPA method, the impact of the dissolution media and
the effect of the solid-state form on solubility were studied.
Moreover, an estimation of the free-energy difference between
the two polymorphic forms was made.
■ MATERIALS AND METHODS
Materials. Indomethacin (γ form) was acquired from
Orion Pharma (Espoo, Finland). Hydrochloric acid (98%),
acetic acid (≥99.85%), phosphorus pentoxide, and sodium
chloride were acquired from Sigma-Aldrich (St. Louis, MO).
FaSSIF/FeSSIF/FaSSGF biorelevant powder was acquired
from Biorelevant (London, U.K.).
Preparation of α and γ Forms. The γ form of
indomethacin was used without further purification or
processing. The α form of indomethacin was prepared by
dissolving γ indomethacin powder in a 50% (v/v) EtOH/Milli-
Q water mixture, followed by slow evaporation of the solvent,
which is a modification of the method used by Kaneniwa et
al.21 The obtained crystals were collected and stored over
phosphorus pentoxide at ambient temperature.
Dissolution Media. Three kinds of media of pH 1.6 (i.e.,
HCl; fasted-state simulated gastric fluid, FaSSGF; and blank
FaSSGF, FaSSGFblk) were prepared according to the
instructions of the manufacturer (Biorelevant, London,
U.K.). Furthermore, two kinds of media of pH 5.0 were
prepared: fed-state simulated intestinal fluid (FeSSIF) and
blank FeSSIF (FeSSIFblk). FaSSGF and FeSSIF biorelevant
media were selected to represent a physiological environment
with surfactant molecules present below and above the critical
micellar concentration, respectively. The detailed compositions
of the media are listed in Table 1.
Image-Based Solubility Measurements. Dissolution
experiments utilizing the SPA method were performed using
a custom-made flow-through setup (Figure 1). The experi-
ments were conducted at room temperature (22 °C) rather
than at 37 °C in order to ensure controlled experimental
conditions. The setup enables the trapping of particles under
constant-flow conditions. In this way, dissolved molecules are
continuously extracted from the chamber, and sink conditions
are maintained. As the measurement can be started as soon as
the solvent comes in contact with the entrapped particles, the
actual solubility of a metastable form can be measured before
any possible solid-state transformation occurs that could affect
the solubility.
In eq 1, at sink conditions, bulk concentration (Cb) can be
disregarded because it is practically zero. This means the
dissolution rate (dm/dt) is dependent only on the equilibrium
solubility at the interface (CS); k is the setup-dependent
transport-rate constant determined as described by Svanbac̈k.20
m
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For a single measurement, approximately 10 mL of
dissolution medium and less than 0.1 mg of sample were
used. Online images were acquired over 15 min through the
transparent part of the flow-through chamber using a USB
microscope (Gigastone S1-100, Irvine, CA). At least five
particles per solid-state form per medium were measured. For
the analysis of the image data, a MatLab script was previously
developed by Svanbac̈k and co-workers.20,22 The script enables
quantification of the particle’s morphology change (i.e.,
dissolution rate) and, consequently, calculation of the
solubility according to eq 1.
Shake-Flask Solubility Measurements. The solubilities
of α and γ indomethacin were measured by the conventional
Table 1. Composition and Properties of Prepared Mediaa
HCl FaSSGFblk FaSSGF FeSSIFblk FeSSIF
pH 1.6 1.6 1.6 5.0 5.0
ionic strength 0.03 M 0.06 M 0.06 M 0.30 M 0.32 M
acetic acid    144 mM 144 mM
lecithin   0.02 mM  3.75 mM
Na-taurocholate   0.08 mM  15 mM
NaCl  34.2 mM 34.2 mM 203 mM 203 mM
HCl 25.1 mM 25.1 mM 25.1 mM  
NaOH    101.0 mM 101.0 mM
aFaSSGF: fasted-state simulated gastric fluid, FeSSIF: fed-state simulated intestinal fluid, FaSSGFblk: blank FaSSGF, FeSSIFblk: blank FeSSIF.
Figure 1. Scheme of the flow-through device (not to scale). Blue
arrows present the flow of the solvent. Particles of the compound
being analyzed are immobilized in the flow-through chamber. Light
access is enabled through the window on the bottom, and imaging of
the particles is enabled through the glass window on the top.
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shake-flask method in HCl (pH 1.6), FaSSGFblk, and FeSSIFblk.
A detailed description of the methodology can be found in the
Supporting Information on page S-2.
X-ray-Powder Diffraction (XRPD). XRPD diffractograms
were recorded using an Empyrean diffractometer (Malvern
Panalytical B.V., Almelo, The Netherlands) with Cu Kα
radiation (λ = 1.54 Å) and a divergence slit of 1/8°. Samples
were packed into the aluminum holder and measured at 45 kV
and 40 mA from 5 to 35° (2θ) with a step size of 0.0066°.
Differential-Scanning Calorimetry (DSC). DSC experi-
ments were performed using a DSC823e (Mettler-Toledo,
Greifensee, Switzerland) equipped with a refrigerated cooling
system (Julabo FT 900, Seelbach, Germany). Nitrogen was
used as a purge gas (50 mL/min).
Samples (2−5 mg) were tightly packed into standard
aluminum crucibles (40 μL) with pierced lids. Two different
procedures were used in these measurements. For determi-
nation of melting temperature and enthalpy, the samples were
equilibrated at 25 °C for 3 min and then linearly heated with a
heating rate of 10 °C/min to 180 °C. For determination of
heat capacities, the samples were equilibrated at 140 °C and
then heated up to 180 °C using a TOPEM-modulated heating
program with a heating rate of 1 °C/min and a pulse height of
1 °C. Samples were measured in triplicate, and thermal events
were analyzed using STARe software (Mettler-Toledo,
Greifensee, Switzerland). Temperatures of melting, enthalpies
of melting, and heat capacities were used to estimate the free-
energy difference between the α and γ polymorphs.
Fourier-Transform Infrared (FT-IR) and Time-Re-
solved Raman Spectroscopy. FT-IR measurements were
conducted using a Burker Vertex 70 spectrometer (Burker
Optik, Ettlingen, Germany). The spectrometer was coupled
with an attenuated-total-reflectance (ATR) accessory, a single-
reflection diamond crystal (MIRacle, Pike Technologies,
Madison, WI). The final spectrum was the mean of 128
scans with a resolution of 2 cm−1 and a spectral range from 650
to 4000 cm−1. The absorbance spectra were obtained using
OPUS software (v. 5.0, Burker Optik, Ettlingen, Germany).
The time-resolved Raman measurements were performed
using a TG532 M1 Raman Spectrometer System (TimeGate
Instruments, Oulu, Finland). The average power used was 60
mW, the pulse width was 150 ps, the spot size was 85 μm, and
the repetition rate was 40 kHz. Samples were packed in an
aluminum holder and measured. During the measurements, the
focal point was moved continuously using a SampleCube
provided by TimeGate Instruments (Oulu, Finland). The
spectral range was recorded at 11 consecutive detector
positions from 900 to 1800 cm−1. The data was processed
using a MatLab-based program provided by TimeGate
Instruments (Oulu, Finland).
Scanning Electron Microscopy. Samples were placed on
a sample holder using double-sided carbon adhesive tape.
Upon adhesion, samples were coated with platinum in a high-
vacuum evaporator (Q150TS, Quorum Technologies, Lewes,
U.K.) and imaged with a Quanta 250 FEG SEM (FEI
Company, Hillsboro, OR). Images were taken with 500×
magnification.
■ RESULTS AND DISCUSSION
Characterization of the Solid-State Forms. Results of
the solid-state characterization are presented in Figure 2 and
summarized in Table 2. Spectroscopic and thermal analyses of
the samples were in good agreement with previously reported
data on the thermodynamically metastable α and stable γ solid-
state forms of indomethacin.23−26 Moreover, experimental
XRPD diffractograms of the α and γ forms coincide with those
reported in the Cambridge Structural Database (INDMET02
and INDMET01, respectively).
The benzoyl-stretching mode, listed in Table 2, represents
the difference in H-bonding in the α and γ crystals. The two
stretching modes of the CO groups, H-bonded and non-H-
bonded, are present in α crystals, and only one stretching
mode, non-H-bonded, is present in γ crystals.26 The difference
Figure 2. XRPD diffractograms (a), FT-IR and Raman spectra (b),
and DSC thermograms (c) of the α and γ solid-state forms of
indomethacin.
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in H-bonding is associated with different orientations of the
molecules in the crystalline lattice. This difference on the
molecular scale is translated to the macroscopically distinct
shapes of α and γ crystals. In Figure 3, needle-shaped α crystals
can be clearly distinguished from prismatic γ crystals.
SPA-Method Solubility Measurements: Impact of the
Solid-State Form. Using the image-based SPA method, the
solubilities of the α and γ solid-state forms of indomethacin in
selected media were measured (Figure 4). In the time span of
the measurements, there were constant increases in dissolved
mass for both solid-state forms. Hence, it was concluded that
no solid-state change took place that would affect the solubility
of the dissolving form. Moreover, no effect of particle
morphology on the SPA solubility values was found
(Supplementary Figures S1 and S2). Therefore, the apparent
equilibrium solubility of the α form and the thermodynamic-
equilibrium solubility of the γ form were measured. Addition-
ally, the solubilities of α and γ indomethacin were also
measured by the conventional shake-flask method (Supple-
mentary Table S1 and Figures S3 and S4).
The ratio of α- to γ-solid-state-form solubility was constant
at 3.3 ± 0.5 in all of the studied media. The observed ratio was
higher than the value of 1.7 ± 0.4 obtained by the shake-flask
experiment in this study (Supporting Information, page S-2).
Moreover, the ratio was also higher than the 1.1 value obtained
by Hancock et al., where the α- to γ-solubility ratio was
measured in 200 mL of deionized water at 45 °C using a flat-
bottomed, water-jacketed, glass vessel with a propeller stirrer.9
Their samples were withdrawn at regular intervals through a
0.22 μm filter and diluted with a standard solution of
indomethacin in 50:50 methanol/water, and the concentration
was measured by UV−visible spectrometry. Both procedures,
the shake-flask experiment conducted in this study and the one
performed by Hancock et al., have several more steps when
compared with the straightforward SPA method. Nevertheless,
Hancock et al. also found that the reported solubility ratio of
crystalline polymorphs varies between 1.1 and 4.0, which is in
agreement with the α- to γ-solubility ratio observed in this
study.
The constant solubility ratio in HCl, FaSSGFblk, FaSSGF,
FeSSIFblk, and FeSSIF media indicates that changes in the
ionic strength, pH, or surfactant concentration of the medium
affect the solubility of both indomethacin crystalline solid-state
forms to the same extent.
SPA-Method Solubility Measurements: Impact of the
Dissolution Media. To evaluate the impact of the dissolution
media, ratios of the average solubility values (RS) of the same
indomethacin solid-state form measured in different media
were calculated (eq 2). Sx and Sy are the average solubility
values in media x and y. It must be noted that the standard
deviation of the calculated ratios is relatively large and most
likely results from the particulate nature of the SPA
measurement, discussed in more detail in the Particle Statistics
section.
R
S
SS
x
y
=
(2)
The composition of the dissolution media affects the
solubility of indomethacin. At pH 1.6, an increase in the
ionic strength of the dissolution medium (from HCl to
FaSSGFblk) resulted in decreases in the solubilities of both
solid-state forms (Table 3). On the other hand, the addition of
surfactants (from FaSSGFblk to FaSSGF) resulted in 2.1 and
Table 2. Unique XRPD Peaks, Benzoyl-CO-Stretching-Mode Vibrations, and Thermal Properties of the α and γ
Indomethacin Solid-State Formsa
XRPD CO-stretching mode (cm−1) DSC
solid-state form unique peak positions (°, 2θ) FT-IR Raman Tm (°C) ΔHm (J/g) Cp (J/(g K)) Cp,L (J/(g K))
α form 6.9, 8.4, 14.2 1680, 1649 1684, 1646 152.8 ± 0.1 97.5 ± 2.6 2.3 ± 0.4 2.0 ± 0.4
γ form 12.7, 16.7, 21.8 1690 1699 159.1 ± 0.1 106.3 ± 1.5 1.7 ± 0.2 2.1 ± 0.1
aTm: melting point, ΔHm: melting enthalpy, Cp: heat capacity, Cp,L: heat capacity upon melting.
Figure 3. SEM image of the α (left) and γ (right) solid-state forms of
indomethacin.
Figure 4. Solubility of indomethacin α and γ solid-state forms in
media with pH 1.6 (a) and media with pH 5.0 (b) as measured with
the SPA method. The effects of pH and surfactants (FaSSGF and
FeSSIF) on solubility can be noted. FaSSGF: fasted-state simulated
gastric fluid, FeSSIF: fed-state simulated intestinal fluid, FaSSGFblk:
blank FaSSGF, FeSSIFblk: blank FeSSIF.
Table 3. Ratios of Average Solubility Values Obtained with
the Image-Based SPA Method for the Same Solid-State
Form Measured in Different Solvents
solubility ratio (RS) α form γ form
FaSSGFblk/HCl 0.4 0.4
FaSSGF/HCl 0.9 1.0
FaSSGF/FaSSGFblk 2.1 2.5
FeSSIF/FeSSIFblk 5.6 4.0
aSPA: single-particle analysis, HCl: HCl pH 1.6, FaSSGFblk: blank
FaSSGF, FeSSIFblk: blank FeSSIF.
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2.5 times higher solubilities of the α and γ forms.
Consequently, increases in both the ionic strength of the
dissolution medium and the surfactant concentration (from
HCl to FaSSGF) cancel each other out and do not have a
significant impact on solubility.
In FeSSIF, the concentrations of sodium taurocholate and
lecithin were above their respective critical micellar concen-
trations (CMC).27,28 Therefore, surfactant molecules were
arranged in micelles, spherical structures in which the
hydrophilic regions (heads) are in contact with the solvent,
and the hydrophobic regions (chains) are contained within the
micelle center. In FaSSGF, the concentrations of sodium
taurocholate and lecithin are below the CMC. Thus, micelles
were not formed. The occurrence of micelles in dissolution
media (from FeSSIFblk to FeSSIF) resulted in 5.6- and 4.0-fold
increases of the α- and γ-form solubilities, respectively. A
similar increase (7.3-fold) in the solubility of the γ form at 37
°C using a μDISS profiler was also measured by Fagerberg and
co-workers.15 From a physicochemical perspective, the
solubility was increased because of the two following
phenomena: lowering of the solvent’s surface tension (in
both FeSSIF and FaSSGF) and distribution of hydrophobic
indomethacin molecules inside the micelles (only in FeSSIF).
Particle Statistics. Because of the large relative standard
deviations (RSD) of the collected data (55 ± 15%), the
Mann−Whitney test was used to determine if the measured
particles of the α and γ forms belong to two separate
populations. The results (Table 4) show that there is a
significant difference in the solubility values of the α and γ
forms in all of the five media used. Therefore, despite the
relatively large RSDs between the solubilities of individual
particles measured with the image-based SPA method, the
samples were still distinct enough to show that they belong to
different populations and therefore different solid-state forms
of indomethacin.
One of the reasons for the high RSD values can be the SPA
method itself, which is still in the development process. With
further improvements in the experimental setup, control of
experimental conditions, and image quality, the RSD may be
reduced. Nevertheless, one should consider another aspect of
this phenomenon. At its core, the SPA method measures the
solubility of individual particles, and the solubility of the
compound is the average of the solubility values of all the
single particles measured.
In principle, the equilibrium solubility in the shake-flask
method is reached after an equilibration period of up to several
days, during which a compound is transformed into its most
thermodynamically stable form with the lowest solubility.29
With the image-based SPA method, even the equilibrium
solubility of the thermodynamically stable γ solid-state form
was approached in a dynamic manner in a matter of minutes,
without any equilibration period.
Even if the compound is in its most stable solid-state form,
the surface energy of individual particles is not unity, but it
most likely follows the Maxwell−Boltzmann distribution.30
Therefore, a single solid-state form presents a population of
particles, of which each has a slightly different surface energy.
To our knowledge, this could also contribute to the high
variation of the solubility data collected with the SPA method
compared with that of the shake-flask method, where this
particle-to-particle energy difference is already averaged out by
using several milligrams of a compound and thus a multitude
of particles.31 It should also be noted that the uncertainty of
solubility values reported in the literature is in the range of 0.6
log units.32 In contrast, the uncertainty of the SPA measure-
ments was 0.26 log units.
Estimation of the Free-Energy Difference between
Polymorphs. The free-energy difference between two
polymorphs can be estimated from their melting data or
their respective solubility values. For the former, according to
Yu et al.,6 to estimate the difference in enthalpy (ΔHm) and
entropy (ΔSm) of the melting process, eqs 3 and 4,
respectively, can be used under two conditions: (a) the
difference between the melting points of the polymorphs is less
than 20 K (it is 6.3 K for α and γ indomethacin) and (b) (Cp,L
− Cp,γ) is assumed to be constant.
H H H C C T T( )( )m m, m, p,L p, m, m,Δ = Δ − Δ + − −α γ γ γ α
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In eqs 3 and 4, ΔHm,x is the melting-enthalpy change, and
Tm,x is the melting temperature of the respective polymorphic
form. Cp,L and Cp,γ are the heat capacities of the supercooled
liquid state and γ form, respectively. By combining eqs 3 and 4
with the well-established relation ΔG0 = ΔH − TΔS, we obtain
eq 5, where ΔG0 is the free-energy difference at Tm,α.
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To extrapolate the ΔG to room temperature, a correction for
nonlinearity has to be made if (Cp,γ − Cp,α) ≠ 0, as is the case
with α and γ indomethacin polymorphs (Table 2). In this
place, eq 6, also derived by Yu et al.,6 can be used, where (Cp,γ
− Cp,α)0 is the value of (Cp,γ − Cp,α) at Tm,α. A reasonable
estimate of this value can be made by subtracting the heat-
capacity changes upon melting, (Cp,L − Cp,α) and (Cp,L − Cp,γ).
G T G S T T
C C T T
T
( ) ( )
( ) ( )
2
0 0 m,
p, p, 0 m,
2
m,
Δ = Δ − Δ −
−
− −
α
γ α α
α (6)
The estimated ΔG between the α and γ polymorphs
amounts to 12 ± 7 J/g. The high standard error of the results
Table 4. Solubility Values of the α and γ Forms of
Indomethacin in Different Media and Results of Multiple
Mann−Whitney Tests
solubility (mg/L) p-value
solvent α form γ form α vs γ
HCl 0.34 ± 0.20 0.10 ± 0.05 0.001
FaSSGFblk 0.14 ± 0.09 0.04 ± 0.03 0.001
FaSSGF 0.29 ± 0.16 0.10 ± 0.02 0.026
FeSSIFblk 2.79 ± 1.67 0.94 ± 0.58 0.001
FeSSIF 15.7 ± 10.4 3.80 ± 1.74 0.009
aHCl: HCl pH 1.6, FaSSGFblk: blank FaSSGF, FeSSIFblk: blank
FeSSIF, p-value: significance level (significant at p < 0.05).
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represents the imprecision of the above free-energy-difference
estimation, which originates from an attempt to precisely
measure a small energy difference of a process with high energy
content: melting.
On the other hand, the ΔG between the polymorphs is
directly proportional to their solubilities.7 Therefore, the
estimation of the free-energy difference can also be obtained
using eq 7, with R, T, and Sx being the gas constant, the
ambient temperature, and the solubilities of the polymorphs,
respectively. Inserting the α- to γ-solubility ratio obtained with
the SPA method into eq 7, a value of 8 ± 1 J/g is obtained.
The result is more precise, and it fits in the range of 12 ± 7 J/g.
G R T
S
S
ln
i
k
jjjjjj
y
{
zzzzzzΔ = × ×
α
γ (7)
The metastable α polymorph has a higher energy content
than the stable γ polymorph, and the difference exceeds
randomizing thermal energy. The thermal energy (ET) of a
system at room temperature is calculated as ET = R × T22°C =
2.45 kJ/mol. The magnitude of ET can be used as a rough
indicator of the interaction strength between molecules.30 This
means that if the interaction energy or, in our case, the
difference in free energy, ΔG, exceeds ET, it will overcome the
opposing disorganizing effect of thermal motion. The
calculated ΔG from the solubility ratios of the α and γ
polymorphs expressed in molar units amounts to 2.9 kJ/mol,
whereas the shake-flask solubility ratios give a value of 1.3 kJ/
mol. It is well-known that the α form of indomethacin is stable
at room temperature, which would substantiate the result
obtained by the theoretical estimation based on DSC
measurements and the SPA method.
■ CONCLUSIONS
In this study, the SPA method was proven capable of
determining the solubility of two different solid-state forms
of the same drug compound. The solubility ratio of the α to γ
solid-state forms of indomethacin is constant at 3.3 ± 0.5 and
is not affected by pH, ionic-strength, or surfactant-concen-
tration changes below or above CMC. Therefore, the only
factor affecting the solubility ratio is the ΔG (2.9 kJ/mol)
between the two polymorphs.
The use of biorelevant media resulted in significantly higher
solubility values when compared with the respective values in
aqueous blank media. This indicates that for a solubility study
aiming to estimate solubility, bioavailability, or BCS classi-
fication, biorelevant dissolution media should be used over
blank aqueous buffers.
Finally, the SPA method can be characterized as a quick-
turnover and low-solvent- and low-substance-consumption
method, thus making it a highly appealing research tool
when it comes to polymorph-solubility screening.
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Anal. 2008, 46, 335−341.
(32) Jorgensen, W. L.; Duffy, E. M. Adv. Drug Delivery Rev. 2002, 54,
355−366.
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.8b05290
Anal. Chem. 2019, 91, 3997−4003
4003
